Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease in terms of molecular pathogenesis and cell of origin. Earlier prognostic models relied mainly on such clinical variables as age

stage of disease

and performance status

which did not display its heterogeneity. Many studies have reported that some biomarkers could be used for prognostication

while older prognostic models need to be revalidated and modified as improved therapeutic options become available. In this review

we discussed pertinent studies on individual biomarkers and pattern-based biomarker models

with an emphasis on markers evaluated in patients treated with rituximabcontaining chemotherapy.